Abstracts from our recent conferences
- Sarapulov A, Serganova I, Bucktrout R, Isshiki Y, Santella A, Rodriguez M-A, Chakraborty S, Brunschvig S, Vardhana S, Lesokhin A, Tripodo C, Melnick A, Beguelin W, Zappasodi R. “Mechanisms of action of immune checkpoint blockade therapy in EZH2/Bcl2-mutant B-cell lymphomas.” AACR International Meeting on Advances in Malignant Lymphoma 2024.
- Schreier A, Zappasodi R, Serganova I, Arcos LM, Zhou XK, Andreopoulou E, Cristofanilli M. “Predictive value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with triple negative breast cancer treated with pembrolizumab.” SABC Annual Meeting 2023.
- Mangarin LM*, Martis S*, Orlando A*, Schad S, Wolchok JD, Greenbaum B, Merghoub T, Zappasodi R. “PD-1hiFoxp3-CD4+ tumor-infiltrating T-cell lineage commitment impacts the immunotherapy outcome.” SITC Annual Meeting 2023; *equal contribution.
- Serganova I, Kang JH, Schreier A, Santella A, Manova-Todorova K, Blasberg R, Demaria S, Merghoub T, Zappasodi R. “The link between tumor metabolic state, TME and immunotherapy response in breast cancer.” CICON Annual Meeting 2023.
- Serganova I, Bucktrout R, Isshiki Y, Chakraborty S, Sarapulov A, Qualls D, Vardhana S, Lesokhin A, Melnick A, Beguelin W, Zappasodi R. “Enhancing T-cell responses to GCB-like lymphomas with immune-checkpoint-blockade-based therapies.” ICML Annual Meeting 2023.
- Mok L, Orlando A, Lehrer J, Stuart J, Rudqvist N-P, Vincent B, Monette A, Senbabaoglu Y, Smith K, Thomas P, Tschernia N, Thorsson V, Zappasodi R and Jonsson V. “A pan-cancer multi-omic immune single-cell atlas for cancer immunotherapy: focus on CD4+ T cells.” SITC Annual Meeting 2022.
